Blue Bird Corporation remains a “Strong Buy” due to its solid backlog, strong funding, and undervaluation, despite recent ...

Good day, ladies and gentlemen. Welcome to the First Quarter of Fiscal Year 2025 Financial Results Conference Call for NeuroOne Medical Technologies Corporation. Today’s call will be […] ...

Goldman Sachs adjusted its outlook on Willis Towers Watson (NASDAQ:WTW), reducing the 12-month price target to $378 from the previous figure. Despite the adjustment, the firm maintained a Buy rating ...

Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been ...

There was good news for online retail giant Amazon (AMZN) today, as it surpassed Walmart (WMT) in revenue. But the news ...

Q2 2025 Earnings Call Transcript February 6, 2025 IBEX Limited beats earnings expectations. Reported EPS is $0.59, ...

The Nasdaq shows signs of uncertainty, with price action indicating a potential slowdown amid trade war concerns. See why I ...

A look at the shareholders of Lucid Group, Inc. (NASDAQ:LCID) can tell us which ... While the precise definition of an insider can be subjective, almost everyone considers board members to be ...

There are no directors' trades from BetaShares NASDAQ 100 ETF (NDQ). Please use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities. What is the ...

Nasdaq Verafin’s data consortium continues ... ARR does not have any standardized definition and is therefore unlikely to be comparable to similarly titled measures presented by other companies.

Maze Therapeutics begins Phase 2 trial for kidney disease drug By Investing.com - Feb 07, 2025 SOUTH SAN FRANCISCO – Maze Therapeutics, Inc. (NASDAQ: MAZE), a clinical-stage biopharmaceutical ...